Improving vaccines by incorporating immunological coadjuvants

While vaccination continues to be the most successful interventionist health policy to date, infectious disease remains a significant cause of death worldwide. A primary reason that vaccination is not able to generate effective immunity is a lack of appropriate adjuvants capable of initiating the desired immune response. Adjuvant combinations can potentially overcome this problem; however, the possible permutations to consider, which include the route and kinetics of vaccination, as well as combinations of adjuvants, are practically limitless. This review aims to summarize the current understanding of adjuvants and related immunological processes and how this knowledge can and has been applied to the strategic selection of adjuvant combinations as components of vaccines against human infectious disease.

[1]  N. Lycke,et al.  Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses. , 1999, Journal of immunology.

[2]  Bali Pulendran,et al.  Translating Innate Immunity into Immunological Memory: Implications for Vaccine Development , 2006, Cell.

[3]  Rino Rappuoli,et al.  Vaccine manufacturing: challenges and solutions , 2006, Nature Biotechnology.

[4]  M. Lifton,et al.  Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. , 2004, The Journal of clinical investigation.

[5]  R. Gupta,et al.  In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. , 1996, Vaccine.

[6]  J. Berzofsky,et al.  A push–pull approach to maximize vaccine efficacy: Abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  C. Dye,et al.  The Development and Impact of Tuberculosis Vaccines , 2006, Cell.

[8]  H. Lewin,et al.  DNA-Encoded Fetal Liver Tyrosine Kinase 3 Ligand and Granulocyte Macrophage-Colony-Stimulating Factor Increase Dendritic Cell Recruitment to the Inoculation Site and Enhance Antigen-Specific CD4+ T Cell Responses Induced by DNA Vaccination of Outbred Animals1 , 2002, The Journal of Immunology.

[9]  A. Iwasaki,et al.  Cutting Edge: Plasmacytoid Dendritic Cells Provide Innate Immune Protection against Mucosal Viral Infection In Situ1 , 2006, The Journal of Immunology.

[10]  S. Gurunathan,et al.  DNA vaccines: immunology, application, and optimization*. , 2000, Annual review of immunology.

[11]  A. Iwasaki,et al.  Enhanced CTL responses mediated by plasmid DNA immunogens encoding costimulatory molecules and cytokines. , 1997, Journal of immunology.

[12]  S. Reed,et al.  Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, Mtb72F, Delivered as Naked DNA or Recombinant Protein1 , 2004, The Journal of Immunology.

[13]  F. Polack,et al.  Successful DNA immunization against measles: Neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles , 2000, Nature Medicine.

[14]  S. M. Sadat,et al.  HCV core protein immunization with Montanide/CpG elicits strong Th1/Th2 and long-lived CTL responses. , 2007, Biochemical and biophysical research communications.

[15]  J. Schlom,et al.  Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. , 2007, Vaccine.

[16]  K. Rajewsky,et al.  Memory B-cell persistence is independent of persisting immunizing antigen , 2000, Nature.

[17]  D. Kozbor,et al.  Oral vaccination with modified vaccinia virus Ankara attached covalently to TMPEG-modified cationic liposomes overcomes pre-existing poxvirus immunity from recombinant vaccinia immunization. , 2007, The Journal of general virology.

[18]  Michael G. Katze,et al.  Viruses and interferon: a fight for supremacy , 2002, Nature Reviews Immunology.

[19]  Stephen P. Schoenberger,et al.  Naïve CTLs require a single brief period of antigenic stimulation for clonal expansion and differentiation , 2001, Nature Immunology.

[20]  K. Schön,et al.  The ADP-Ribosylating CTA1-DD Adjuvant Enhances T Cell-Dependent and Independent Responses by Direct Action on B Cells Involving Anti-Apoptotic Bcl-2- and Germinal Center-Promoting Effects1 , 2000, The Journal of Immunology.

[21]  R. Compans,et al.  Mucosal Immunization with Virus-Like Particles of Simian Immunodeficiency Virus Conjugated with Cholera Toxin Subunit B , 2003, Journal of Virology.

[22]  P. Sinko,et al.  Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. I. In vitro characterization. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[23]  A. Kelleher,et al.  Randomised, Placebo-Controlled, Phase I/IIa Evaluation of the Safety and Immunogenicity of Fowlpox Virus Expressing HIV gag-pol and Interferon-? in HIV-1 Infected Subjects , 2005, Human vaccines.

[24]  B. Kwon,et al.  Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. , 2006, International immunology.

[25]  D. Montefiori,et al.  Protection by SIV VLP DNA prime/protein boost following mucosal SIV challenge is markedly enhanced by IL‐12/GM‐CSF co‐administration , 2002, Journal of medical primatology.

[26]  K. Schön,et al.  CTA1-DD-Immune Stimulating Complexes: a Novel, Rationally Designed Combined Mucosal Vaccine Adjuvant Effective with Nanogram Doses of Antigen1 , 2001, The Journal of Immunology.

[27]  B. Beutler,et al.  Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling , 2006, Science.

[28]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[29]  M. Beer,et al.  Recombinant virus-expressed bovine cytokines do not improve efficacy of a bovine herpesvirus 1 marker vaccine strain. , 2003, Vaccine.

[30]  J. Villadangos,et al.  Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. , 2006, Immunity.

[31]  G. Pialoux,et al.  [HIV vaccines]. , 2005, Presse medicale.

[32]  I. M. Belyakov,et al.  Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines. , 2003, Current molecular medicine.

[33]  J. Yewdell,et al.  Understanding presentation of viral antigens to CD8+ T cells in vivo: the key to rational vaccine design. , 2005, Annual review of immunology.

[34]  O. Beretta,et al.  Dendritic cells in pathogen recognition and induction of immune responses: a functional genomics approach , 2006, Journal of leukocyte biology.

[35]  B. Pulendran.  Division of labor and cooperation between dendritic cells , 2006, Nature Immunology.

[36]  A. Abbas,et al.  Control of CD4+ T‐cell memory by cytokines and costimulators , 2006, Immunological reviews.

[37]  L. McHeyzer-Williams,et al.  Antigen-specific memory B cell development. , 2005, Annual review of immunology.

[38]  M. Bevan,et al.  Effector and memory CTL differentiation. , 2007, Annual review of immunology.

[39]  H. Alpár,et al.  Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A. , 2006, Vaccine.

[40]  A. Khoruts,et al.  CTLA-4 blockade reverses CD8+ T cell tolerance to tumor by a CD4+ T cell- and IL-2-dependent mechanism. , 1999, Immunity.

[41]  M. Bevan,et al.  CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection , 2004, Nature Immunology.

[42]  Theodore C Eickhoff,et al.  Workshop summary. Aluminum in vaccines. , 2002, Vaccine.

[43]  F. Aoki,et al.  Glycoprotein-D-adjuvant vaccine to prevent genital herpes. , 2002, The New England journal of medicine.

[44]  C. Kensil,et al.  Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations. , 1997, Vaccine.

[45]  K. Lövgren,et al.  The Combined CTA1-DD/ISCOMs Vector Is an Effective Intranasal Adjuvant for Boosting Prior Mycobacterium bovis BCG Immunity to Mycobacterium tuberculosis , 2006, Infection and Immunity.

[46]  E. Agger,et al.  Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31. , 2006, Vaccine.

[47]  J. Banchereau,et al.  Flt3-Ligand and Granulocyte Colony-Stimulating Factor Mobilize Distinct Human Dendritic Cell Subsets In Vivo1 , 2000, The Journal of Immunology.

[48]  H. Alpár,et al.  Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation. , 2005, Vaccine.

[49]  M. Bajénoff,et al.  Repeated Antigen Exposure Is Necessary for the Differentiation, But Not the Initial Proliferation, of Naive CD4+ T Cells1 , 2002, The Journal of Immunology.

[50]  T. Kipps,et al.  Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines. , 2001, Vaccine.

[51]  W. Gillanders,et al.  Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[52]  Susan M. Kaech,et al.  Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells , 2001, Nature Immunology.

[53]  J. Sadoff,et al.  Advances in tuberculosis vaccine strategies , 2006, Nature Reviews Microbiology.

[54]  L. O’Neill,et al.  TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. , 2006, Trends in immunology.

[55]  T. Brocker,et al.  Concerted antigen presentation by dendritic cells and B cells is necessary for optimal CD4 T‐cell immunity in vivo , 2005, Immunology.

[56]  A. Mowat,et al.  Dendritic cell maturation enhances CD8+ T‐cell responses to exogenous antigen via a proteasome‐independent mechanism of major histocompatibility complex class I loading , 2003, Immunology.

[57]  J. Treanor,et al.  Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination of healthy adults. , 1999, The Journal of infectious diseases.

[58]  Shizuo Akira,et al.  IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. , 2006, Vaccine.

[59]  M. Giuliani,et al.  Enhancement of Protective Efficacy following Intranasal Immunization with Vaccine Plus a Nontoxic LTK63 Mutant Delivered with Nanoparticles , 2002, Infection and Immunity.

[60]  M. Pearse,et al.  The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses. , 2007, Vaccine.

[61]  C. Janeway,et al.  Innate immune recognition. , 2002, Annual review of immunology.

[62]  J. Heeney,et al.  Cytotoxic T cells and neutralizing antibodies induced in rhesus monkeys by virus-like particle HIV vaccines in the absence of protection from SHIV infection. , 1998, Virology.

[63]  H. Wiker,et al.  Vaccine Approaches to Prevent Tuberculosis , 2006, Scandinavian journal of immunology.

[64]  R. Ball.  Methods of ensuring vaccine safety , 2002, Expert review of vaccines.

[65]  R. Coffman,et al.  Brief Definitive Report TRANSFORMING GROWTH FACTOR # SPECIFICALLY ENHANCES IgA PRODUCTION BY LIPOPOLYSACCHARIDE-STIMULATED , 2022 .

[66]  J. Roes,et al.  TGF-β Receptor Controls B Cell Responsiveness and Induction of IgA In Vivo , 2000 .

[67]  G. Belz,et al.  Cross‐presentation, dendritic cell subsets, and the generation of immunity to cellular antigens , 2004, Immunological reviews.

[68]  P. Rogers,et al.  OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells. , 2001, Immunity.

[69]  C. Biron,et al.  Natural killer cells in antiviral defense: function and regulation by innate cytokines. , 1999, Annual review of immunology.

[70]  Giuseppe Del Giudice,et al.  MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile , 2003, Expert review of vaccines.

[71]  B. Graham,et al.  Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. , 1996, Annals of internal medicine.

[72]  John T. Chang,et al.  Asymmetric T Lymphocyte Division in the Initiation of Adaptive Immune Responses , 2007, Science.

[73]  K. Schwarz,et al.  Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects , 2004, The Journal of Immunology.

[74]  L. Stamatatos,et al.  Increased Level and Longevity of Protective Immune Responses Induced by DNA Vaccine Expressing the HIV-1 Env Glycoprotein when Combined with IL-21 and IL-15 Gene Delivery1 , 2006, The Journal of Immunology.

[75]  H. J. Baker,et al.  Mucosal Immunization with Helicobacter, CpG DNA, and Cholera Toxin Is Protective , 2003, Infection and Immunity.

[76]  Urs Christen,et al.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.

[77]  A. Heath,et al.  Co-stimulatory agonists as immunological adjuvants. , 2006, Vaccine.

[78]  H. Davis,et al.  CPG ODN allows lower dose of antigen against hepatitis B surface antigen in BALB/c mice , 2003, Immunology and cell biology.

[79]  N. Yamaguchi,et al.  Transforming growth factor beta induces IgA production and acts additively with interleukin 5 for IgA production , 1989, The Journal of experimental medicine.

[80]  David A. Anderson,et al.  Virus-like particles: Passport to immune recognition , 2006, Methods.

[81]  P. Hansbro,et al.  Transcutaneous Immunization with Combined Cholera Toxin and CpG Adjuvant Protects against Chlamydia muridarum Genital Tract Infection , 2004, Infection and Immunity.

[82]  Christophe Benoist,et al.  Antigen persistence is required throughout the expansion phase of a CD4+ T cell response , 2005, The Journal of experimental medicine.

[83]  H. Liao,et al.  Cytokine Requirements for Induction of Systemic and Mucosal CTL After Nasal Immunization1 , 2001, The Journal of Immunology.

[84]  D. Philpott,et al.  Nod-like proteins in immunity, inflammation and disease , 2006, Nature Immunology.

[85]  F. Martinon,et al.  NLRs join TLRs as innate sensors of pathogens. , 2005, Trends in immunology.

[86]  P. Hertzog,et al.  Toll-like receptor signalling and the clinical benefits that lie within , 2007, Inflammation Research.

[87]  Sang-Nae Cho,et al.  Enhanced Immunogenicity and Protective Efficacy with the Use of Interleukin-12-Encapsulated Microspheres plus AS01B in Tuberculosis Subunit Vaccination , 2006, Infection and Immunity.

[88]  J. Donnelly,et al.  Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen. , 2002, Vaccine.

[89]  S. Hoffman,et al.  CpG Oligodeoxynucleotide and Montanide ISA 51 Adjuvant Combination Enhanced the Protective Efficacy of a Subunit Malaria Vaccine , 2004, Infection and Immunity.

[90]  M. Alderson,et al.  TLR4 agonists as immunomodulatory agents , 2006, Journal of endotoxin research.

[91]  M. Singh,et al.  A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[92]  N. Escriou,et al.  Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation. , 2004, Blood.

[93]  D. McDonald,et al.  Distribution of adjuvant MF59 and antigen gD2 after intramuscular injection in mice. , 1999, Vaccine.

[94]  T. Ross,et al.  Virus-like particles: designing an effective AIDS vaccine. , 2006, Methods.

[95]  J. Berzofsky,et al.  Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. , 2001, International immunology.

[96]  L. Brown,et al.  ISCOMTM‐based vaccines: The second decade , 2005, Immunology and cell biology.

[97]  Derek T. O'Hagan,et al.  Recent Advances in Vaccine Adjuvants , 2002, Pharmaceutical Research.

[98]  T. Evans,et al.  The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults. , 2002, Vaccine.

[99]  S. Quezada,et al.  CD40/CD154 interactions at the interface of tolerance and immunity. , 2004, Annual review of immunology.

[100]  Shalin H. Naik,et al.  Steady-state and inflammatory dendritic-cell development , 2007, Nature Reviews Immunology.

[101]  H. Liao,et al.  Cytokines as Adjuvants for the Induction of Anti-Human Immunodeficiency Virus Peptide Immunoglobulin G (IgG) and IgA Antibodies in Serum and Mucosal Secretions after Nasal Immunization , 2002, Journal of Virology.

[102]  K. Ishii,et al.  Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses , 2006, Nature.

[103]  C. Reis e Sousa,et al.  Activation of dendritic cells: translating innate into adaptive immunity. , 2004, Current opinion in immunology.

[104]  B. Rouse,et al.  Rescue of memory CD8+ T cell reactivity in peptide/TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. , 2005, Virology.

[105]  R. Kornbluth,et al.  Immunostimulatory combinations: designing the next generation of vaccine adjuvants , 2006, Journal of leukocyte biology.

[106]  R. Rappuoli.  Rational design of vaccines , 1997, Nature Medicine.

[107]  M. Corr,et al.  Plasmid DNA vaccination: Mechanism of antigen presentation , 2004, Springer Seminars in Immunopathology.

[108]  E. B. Lindblad.  Aluminium adjuvants--in retrospect and prospect. , 2004, Vaccine.

[109]  V. A. Stewart,et al.  Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. , 2006, Vaccine.

[110]  D. Kaslow,et al.  Improved Immunogenicity and Efficacy of the Recombinant 19-Kilodalton Merozoite Surface Protein 1 by the Addition of Oligodeoxynucleotide and Aluminum Hydroxide Gel in a Murine Malaria Vaccine Model , 2002, Infection and Immunity.

[111]  H. HogenEsch,et al.  Mechanisms of stimulation of the immune response by aluminum adjuvants. , 2002, Vaccine.

[112]  T. Waldmann,et al.  Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[113]  R. Rappuoli,et al.  Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines , 2003, Expert review of vaccines.

[114]  Jeffrey B Ulmer,et al.  Targeting the innate immune response with improved vaccine adjuvants , 2005, Nature Medicine.

[115]  D. Granoff,et al.  MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine , 1997, Infection and immunity.

[116]  B. Coupar,et al.  Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection , 1987, Nature.

[117]  Yong‐jun Liu,et al.  IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. , 2005, Annual review of immunology.

[118]  T. Braciale,et al.  A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. , 2007, Vaccine.

[119]  D. Cooper,et al.  Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12. , 2004, Vaccine.

[120]  A. Hovav,et al.  Gamma Interferon and Monophosphoryl Lipid A-Trehalose Dicorynomycolate Are Efficient Adjuvants for Mycobacterium tuberculosis Multivalent Acellular Vaccine , 2005, Infection and Immunity.

[121]  J. Melero,et al.  Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. , 2000, Vaccine.

[122]  S. Ascarateil,et al.  Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines , 2002, Expert review of vaccines.

[123]  M. O’Riordan,et al.  Innate recognition of intracellular bacteria. , 2007, Current opinion in immunology.

[124]  V. Khoshoo,et al.  Reduced long‐term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: A preliminary report , 1998, Pediatric pulmonology.

[125]  B. Car,et al.  The Toxicology of Interleukin-12: A Review , 1999, Toxicologic pathology.

[126]  園田 英一朗.  Transforming growth factor β induces IgA production and acts additively with interleukin 5 for IgA production , 1992 .

[127]  Joe D. Cohen,et al.  Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant , 2003, Expert review of vaccines.

[128]  E. Wherry,et al.  Antigen-independent memory CD8 T cells do not develop during chronic viral infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[129]  A. Sher,et al.  Adsorption to aluminum hydroxide promotes the activity of IL-12 as an adjuvant for antibody as well as type 1 cytokine responses to HIV-1 gp120. , 1997, Journal of immunology.

[130]  M. Buti,et al.  Immunogenicity and safety of an experimental adjuvanted hepatitis B candidate vaccine in liver transplant patients , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[131]  Stefania Gallucci,et al.  Natural adjuvants: Endogenous activators of dendritic cells , 1999, Nature Medicine.

[132]  Gunther Hartmann,et al.  5'-Triphosphate RNA Is the Ligand for RIG-I , 2006, Science.

[133]  A. Sher,et al.  Cooperation of Toll-like receptor signals in innate immune defence , 2007, Nature Reviews Immunology.

[134]  M. Esteban,et al.  Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. , 2006, Virus research.

[135]  W. Paul,et al.  Interferon-gamma and B cell stimulatory factor-1 reciprocally regulate Ig isotype production. , 1987, Science.

[136]  M. Houghton,et al.  Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. , 2006, The Journal of general virology.

[137]  G. Belz,et al.  Epidermal Viral Immunity Induced by CD8α+ Dendritic Cells But Not by Langerhans Cells , 2003, Science.

[138]  Xu Liu,et al.  Adjuvant synergy in the response to hepatitis B vaccines. , 2003, Vaccine.

[139]  D. Barouch.  Rational design of gene‐based vaccines , 2006, The Journal of pathology.

[140]  Pengfei Wang,et al.  Synthetic studies of complex immunostimulants from Quillaja saponaria: synthesis of the potent clinical immunoadjuvant QS-21Aapi. , 2006, Journal of the American Chemical Society.

[141]  J. Encke,et al.  Genetic vaccination with Flt3-L and GM-CSF as adjuvants: Enhancement of cellular and humoral immune responses that results in protective immunity in a murine model of hepatitis C virus infection. , 2006, World journal of gastroenterology.

[142]  M. Feinberg,et al.  Expression of CCL20 and Granulocyte-Macrophage Colony-Stimulating Factor, but Not Flt3-L, from Modified Vaccinia Virus Ankara Enhances Antiviral Cellular and Humoral Immune Responses , 2006, Journal of Virology.

[143]  A. Pichlmair,et al.  RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5'-Phosphates , 2006, Science.

[144]  S. Paludan,et al.  Interleukin-21 mRNA expression during virus infections. , 2006, Cytokine.

[145]  A. Stryhn,et al.  Alteration of epitope recognition pattern in Ag85B and ESAT‐6 has a profound influence on vaccine‐induced protection against Mycobacterium tuberculosis , 2006, European journal of immunology.

[146]  H E Junginger,et al.  Chitosan and its derivatives in mucosal drug and vaccine delivery. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[147]  S. Romagnani.  Regulation of the T cell response , 2006, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[148]  F. Martinon,et al.  NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. , 2004, Immunity.

[149]  M. Lievens,et al.  Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. , 2004, Vaccine.

[150]  Shizuo Akira,et al.  Innate immune recognition of viral infection , 2006, Nature Immunology.

[151]  R. Rappuoli,et al.  Novel Approaches to Vaccine Delivery , 2004, Pharmaceutical Research.

[152]  Thomas Matthews,et al.  Safety and Immunogenicity of a Candidate HIV-1 Vaccine in Healthy Adults: Recombinant Glycoprotein (rgp) 120: A Randomized, Double-Blind Trial , 1996, Annals of Internal Medicine.

[153]  S. Akira,et al.  Pathogen recognition with Toll-like receptors. , 2005, Current opinion in immunology.

[154]  F. Ennis,et al.  IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. , 1999, Journal of immunology.

[155]  D. Piedrafita,et al.  DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy. , 2006, Vaccine.

[156]  Michael Y. Gerner,et al.  Signals required for programming effector and memory development by CD8+ T cells , 2006, Immunological reviews.

[157]  A. Sjölander,et al.  Induction of lymphocyte recruitment in the absence of a detectable immune response. , 2000, Vaccine.

[158]  C. Ahonen,et al.  Combined TLR and CD40 Triggering Induces Potent CD8+ T Cell Expansion with Variable Dependence on Type I IFN , 2004, The Journal of experimental medicine.

[159]  Edgar Schmitt,et al.  Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. , 2006, Blood.

[160]  J. Sacarlal,et al.  Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1–4 in Mozambique , 2006, Tropical medicine & international health : TM & IH.

[161]  E. Unanue,et al.  Interferon-producing Cells Fail to Induce Proliferation of Naive T Cells but Can Promote Expansion and T Helper 1 Differentiation of Antigen-experienced Unpolarized T Cells , 2003, The Journal of experimental medicine.

[162]  Brigitte Colau,et al.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.

[163]  I. Frazer.  God's gift to women: the human papillomavirus vaccine. , 2006, Immunity.

[164]  Li Wu,et al.  CD4 and CD8 Expression by Dendritic Cell Subtypes in Mouse Thymus and Spleen1 , 2000, The Journal of Immunology.

[165]  Jonathan M. Austyn,et al.  Dendritic cells , 1998, Current opinion in hematology.

[166]  P. Earl,et al.  Studies on GM-CSF DNA as an adjuvant for neutralizing Ab elicited by a DNA/MVA immunodeficiency virus vaccine. , 2006, Virology.

[167]  J. Brewer.  (How) do aluminium adjuvants work? , 2006, Immunology letters.

[168]  J. Ahlers.  A push-pull approach to maximize vaccine efficacy : abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L , 2002 .

[169]  D. McDonald,et al.  Dendritic cells internalize vaccine adjuvant after intramuscular injection. , 1998, Cellular immunology.

[170]  C. Cooper,et al.  CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study , 2004, Journal of Clinical Immunology.

[171]  P. Sutton,et al.  Saponin-adjuvanted particulate vaccines for clinical use. , 2006, Methods.

[172]  D. Tough,et al.  Direct Stimulation of T Cells by Type I IFN Enhances the CD8+ T Cell Response during Cross-Priming1 , 2006, The Journal of Immunology.

[173]  J. Berzofsky,et al.  Signals delivered through TCR instruct IL-12 receptor (IL-12R) expression: IL-12 and tumor necrosis factor-alpha synergize for IL-12R expression at low antigen dose. , 2001, International immunology.

[174]  K. Rajewsky,et al.  Maintenance of B-cell memory by long-lived cells generated from proliferating precursors , 1990, Nature.

[175]  P. Sinko,et al.  Adjuvancy enhancement of muramyl dipeptide by modulating its release from a physicochemically modified matrix of ovalbumin microspheres. II. In vivo investigation. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[176]  S. Pichyangkul,et al.  Long-Lasting Protective Immune Response to the 19-Kilodalton Carboxy-Terminal Fragment of Plasmodium yoelii Merozoite Surface Protein 1 in Mice , 2007, Clinical and Vaccine Immunology.

[177]  N. Petrovsky,et al.  Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.

[178]  Y. Oh,et al.  Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant. , 2004, Virology.

[179]  P. Fink,et al.  The CD8 response on autopilot , 2001, Nature Immunology.